CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource® (PER®), the leader in hematology and oncology continuing medical education, will host Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies. The live educational symposium will be held on May 19 at 5:30 p.m. at the Moscone Center in San Francisco in conjunction with the American Urological Association’s 2018 annual meeting. The program will be chaired by Daniel P. Petrylak, M.D., a professor of medical oncology and urology, the director of prostate and GU medical oncology, and the director of Prostate Cancer Translational Research Group at Yale Cancer Center.
“In recent years, we have seen new data that supports the use of immuno-oncology strategies in the treatment of bladder cancers, a tumor were the standard of care hadn’t changed in quite some time” said Phil Talamo, the president of PER®. “This satellite symposium will help the urologist understand the latest data and integrate new care strategies for their bladder cancer patients.”
Designed for urologists, oncologists and researchers interested in the treatment of bladder cancers, Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies is an educational symposium. The program provides a review of practice-changing data and its impact on patient care. Attendees will gain insight on immunotherapeutic approaches to managing bladder cancer and patients and the role of biomarkers in contemporary urological cancer care. Attendees will gain insight through real-world interactive clinical case discussions and presentations.
This live CME symposium offers up to 2.0 American Medical Association Physician’s Recognition Award Category 1 Credits™. For more information and to register, visit http://www.gotoper.com/conferences/iobladder18/meetings/advancing-the-treatment-of-bladder-cancers-using-evidence-based-immuno-oncology-strategies.
Since 1995, Physicians’ Education Resource, LLC® (PER®), has been the leading provider of live and online continuing medical education activities on oncology and hematology by providing high-quality, evidence-based activities featuring leading experts who focus on the application of practice-changing advances. In 2018, PER® will develop and implement 20 historic annual legacy conferences in the United States and Europe, along with many world-renowned online learning formats such as Medical Crossfire®. PER is accredited by both the Accreditation Council for Continuing Medical Education (ACCME) and the California Board of Registered Nursing (CBRN). PER® is part of the Cranbury, New Jersey-based MJH Associates, Inc., family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.